Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Benitec Biopharma (BNTC) Shares Outstanding (Weighted Average): 2019-2025

Historic Shares Outstanding (Weighted Average) for Benitec Biopharma (BNTC) over the last 6 years, with Jun 2025 value amounting to $25.6 million.

  • Benitec Biopharma's Shares Outstanding (Weighted Average) rose 173.29% to $25.6 million in Q2 2025 from the same period last year, while for Mar 2025 it was $23.5 million, marking a year-over-year increase of 804.61%. This contributed to the annual value of $25.6 million for FY2025, which is 173.29% up from last year.
  • As of Q2 2025, Benitec Biopharma's Shares Outstanding (Weighted Average) stood at $25.6 million, which was up 9.16% from $23.5 million recorded in Q1 2025.
  • Benitec Biopharma's 5-year Shares Outstanding (Weighted Average) high stood at $25.6 million for Q2 2025, and its period low was $267,086 during Q1 2021.
  • Moreover, its 3-year median value for Shares Outstanding (Weighted Average) was $6.0 million (2024), whereas its average is $10.3 million.
  • Data for Benitec Biopharma's Shares Outstanding (Weighted Average) shows a peak YoY spiked of 804.61% (in 2025) over the last 5 years.
  • Benitec Biopharma's Shares Outstanding (Weighted Average) (Quarterly) stood at $480,688 in 2021, then spiked by 242.42% to $1.6 million in 2022, then surged by 56.29% to $2.6 million in 2023, then spiked by 802.51% to $23.2 million in 2024, then surged by 173.29% to $25.6 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $25.6 million for Q2 2025, versus $23.5 million for Q1 2025 and $23.2 million for Q4 2024.